A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lower blood sugar.
- Who can join
- Children and teens 10 to 17, have type 2 diabetes.
- What you take
- orforglipron, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 3.5 years; your own time in it is usually shorter.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Diabetes Mellitus, Type 2.
Full scientific study title: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes.
Who can join
Children and teens 10 to 17, have type 2 diabetes. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin
- Have HbA1c \> 6.5% to ≤ 11.0% at screening
- Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of \>85th percentile
Key exclusion criteria
- Have type 1 diabetes
- After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome
- Have had at least one episode of severe hypoglycemia and/or at least one episode of hypoglycemic unawareness within the last 6 months before screening
- Have a history of pancreatitis or gallbladder disease
- Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
Where this trial runs
This trial has 17 sites across 10 states. Site contacts are listed for reference. They are not screening through this trial right now.
California2 sites
- Sutter Valley Medical Foundation (SVMF) Pediatric EndocrinologySacramento, California9164261902
- Rady Children's HospitalSan Diego, California8589668940
Connecticut1 site
- Stamford Therapeutics ConsortiumStamford, Connecticut
Georgia2 sites
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics (CAP)Atlanta, Georgia
- CenExel iResearch, LLCDecatur, Georgia4045371281
Idaho1 site
- Medical Research PartnersAmmon, Idaho(208) 522-4600
Kansas1 site
- Cotton O'Neil Diabetes & EndocrinologyTopeka, Kansas785-354-9591
New York2 sites
- SUNY Upstate Medical UniversitySyracuse, New York
- Advantage Clinical TrialsThe Bronx, New York917-962-0234
Oklahoma1 site
- Central States ResearchTulsa, Oklahoma918-645-5400
Pennsylvania1 site
- Frontier Clinical Research, LLCSmithfield, Pennsylvania7245698036
Tennessee1 site
- Vanderbilt Health One Hundred OaksNashville, Tennessee2252265662
Texas5 sites
- Gadolin ResearchBeaumont, Texas409-331-6040
- Driscoll Children's HospitalCorpus Christi, Texas3617397250
- Proactive Clinical Research LLCEdinburg, Texas956-731-1260
- Consano Clinical Research, LLCShavano Park, Texas210-545-4900
- Victoria Clinical Research GroupVictoria, Texas3612107869
Timeline
Scheduled start: September 2026. Expected completion: March 2030. Last updated on ClinicalTrials.gov: August 19, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
